JBC Pharmaceuticals Ltd.

Overview

JBC Pharmaceuticals Ltd. is a private pharmaceutical company specializing in innovative drug development and cutting-edge research. The company focuses on creating therapies that address unmet medical needs in various therapeutic areas.

Therapeutic areas

API / Drug Master Files

JBC Pharmaceuticals Ltd. holds 45 active (57 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• AZATHIOPRINEActive2026-01-03
• VARDENAFIL HYDROCHLORIDEActive2025-12-30
• MYCOPHENOLATE SODIUMActive2025-11-04
• AVANAFILActive2025-10-06
• MYCOPHENOLATE MOFETILActive2025-08-08
• ELETRIPTAN HYDROBROMIDEActive2025-07-21
• DEFERASIROXActive2025-05-24
• IBUPROFEN LYSINEActive2025-04-30
• IBUPROFEN ARGININEActive2025-04-30
• ESCITALOPRAM OXALATE USPActive2024-11-05
• DEXIBUPROFENActive2024-10-21
• CLOZAPINE USPActive2024-05-28
• IBUPROFEN SODIUM DIHYDRATEActive2024-02-06
• PIRFENIDONEActive2022-12-31
• SOLIFENACIN SUCCINATEActive2022-07-15

Showing 15 of 57 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JBC Pharmaceuticals Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.